Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin

Japanese Journal of Clinical Oncology

Volumn 37, Issue 4, 2007, Pages 275-281

  Boku, Narikazu ^a   Ohtsu, Atsushi ^b   Yoshida, Shigeaki ^a   Shirao, Kuniaki ^c   Shimada, Yasuhiro ^c   Hyodo, Ichinosuke ^d   Saito, Hiroshi ^e   Miyata, Yoshinori ^f  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e Yamagata Prefectural Central Hospital   (Japan)

^f Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

Author keywords

5 uorouracil; Cisplatin; Gastric cancer; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; MITOMYCIN C; PROTEIN BCL 2; PROTEIN P53; THYMIDYLATE SYNTHASE; UFT; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PREDICTION; PROGNOSIS; STOMACH CANCER;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; GENES, BCL-2; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; PROGNOSIS; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34447637306     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym015     Document Type: Article

References (30)

1. Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, et al. An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986;4:1799-803.
2. Moertel CG, Rubin J, O'Connel MJ, Schutt AJ, Wieand HS. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986;4:1053-7.
3. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-7.
4. Wilke H, Preusser P, Fink U, Archterrath W, Lenaz L, Stahl M, et al. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 1990;8:65-70.
5. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, et al. A phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous 5-fluorouracil (ECF). Ann Oncol 1994;5:609-16.
6. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K, et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: Report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994;30A:2091-3.
7. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
8. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. A phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23.
9. Cullinan SA, Moertel CG, Wieand H, O'Connell MJ, Poon MA, Krook JE, et al. Controlled evaluation of three drug combination regimen versus fluorouracil alone in the therapy of advanced gastric cancer. J Clin Oncol 1994;12:412-6.
10. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-18.
11. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-9.
12. Ohkuwa M, Ohtsu A, Boku N, Yoshida S, Miyata Y, Shirao K, et al. Long-term results of patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials. Gastric Cancer 2000;3:145-50.
13. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-34.
14. Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995;1:189-98.
15. Nishimura T, Newkirk K, Sessions RB, Andrew PA, Trock BJ, Rasmussen AA, et al. Immunohistochemical staining for gluthathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 1996;2:1859-65.
16. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolkman N, Drake JC, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-7.
17. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998;4:1469-74.
18. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48 Geneva, Switzerland, World Health Organization, 1979.
19. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma (1st Engl. edn). Tokyo, Japan, Kanehara, 1995.
20. Takiuchi H, Hirata I, Kawabe SI, Egashira Y, Katsu K. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep 2000;7:841-6.
21. Nagashima F, Boku N, Ohtsu A, Yoshida S, Hasebe T, Ochiai A, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol 2005;35:714-9.
22. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8.
23. Dvorak HF, Orenstein NS, Carvalho AC, Churchill WH, Dvorak AM, Galli SJ, et al. Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor secreted products. J Immunol 1979;122:166-74.
24. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-863.
25. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47.
26. Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997;132:541-6.
27. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3:1309-16.
28. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindo M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-7.
29. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6:1161-8.
30. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 2000;18:2046-52.